logo-loader

MaxCyte in 'exceptional position to benefit from explosive growth in gene therapy'

Published: 23:27 04 Feb 2020 AEDT

Proactive Research analyst Emma Ulker gives her take on the recent trading update from MaxCyte (LON:MXCT).

The firm signed five of eight clinical/commercial deals for its proprietary cell engineering Flow Electroporation technology in FY19.

Ulker says the increasing momentum in deal flow echoes the 'explosive growth' in the cell and gene therapy sector.

She adds that MaxCyte is in an 'exceptional position' to continue to benefit from the growth of the industry given the versatility of its cell engineering platform.

Click here to read Emma's note on MaxCyte - delivering growth, highlighting value

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

11 hours, 47 minutes ago